Olema Pharmaceuticals, Inc. $OLMA Holdings Cut by Bain Capital Life Sciences Investors LLC

Key Points

• Bain Capital Life Sciences Investors LLC reduced its stake in Olema Pharmaceuticals by 8.4% in the first quarter, now owning approximately 3.8% of the company, making it their 8th largest holding.
• Olema Pharmaceuticals has reported a loss of ($0.51) earnings per share for the last quarter, missing the consensus estimate, with analysts predicting a EPS of -2.33 for the current year.
• Recent changes in price targets by analysts include JPMorgan raising their target from $28.00 to $29.00 and Oppenheimer reducing theirs from $25.00 to $22.00, indicating varying outlooks on the stock's performance.

Bain Capital Life Sciences Investors LLC lessened its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 8.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,843,954 shares of the company's stock after selling 626,260 shares during the period. Olema Pharmaceuticals accounts for approximately 3.8% of Bain Capital Life Sciences Investors LLC's holdings, making the stock its 8th biggest position. Bain Capital Life Sciences Investors LLC owned 10.01% of Olema Pharmaceuticals worth $25,733,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in OLMA. Wells Fargo & Company MN increased its holdings in shares of Olema Pharmaceuticals by 35.5% in the fourth quarter. Wells Fargo & Company MN now owns 22,725 shares of the company's stock worth $132,000 after purchasing an additional 5,958 shares during the last quarter. Barclays PLC increased its holdings in shares of Olema Pharmaceuticals by 21.0% in the fourth quarter. Barclays PLC now owns 114,879 shares of the company's stock worth $669,000 after purchasing an additional 19,964 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Olema Pharmaceuticals by 1,436.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 22,714 shares of the company's stock worth $132,000 after purchasing an additional 21,236 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $58,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $64,000. 91.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on OLMA shares. Oppenheimer reiterated an "outperform" rating and issued a $22.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, September 3rd. The Goldman Sachs Group dropped their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their price target on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, August 14th. Citigroup lifted their price target on Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Finally, Zacks Research upgraded Olema Pharmaceuticals to a "strong sell" rating in a research report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.00.

Olema Pharmaceuticals Trading Down 8.4%

Shares of NASDAQ:OLMA traded down $0.70 during trading on Monday, reaching $7.62. 875,132 shares of the company were exchanged, compared to its average volume of 890,344. The firm has a market capitalization of $522.62 million, a PE ratio of -3.85 and a beta of 1.92. The business's fifty day simple moving average is $5.14 and its 200-day simple moving average is $4.66. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $13.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.09 and a quick ratio of 11.09.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). On average, research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.